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Abstract 
 Signaling molecules have important roles in many cellular functions, but because 
these pathways are incredibly complex, the exact mechanisms often remain unknown. 
One signaling molecule, protein kinase C alpha (PKC), is involved in cell proliferation 
and is expressed at high levels in many cancers. Interestingly, its activity as a tumor 
promoter or tumor suppressor varies depending on the cell type for reasons not yet 
fully understood. This study aimed to investigate the role of PKC in cell proliferation in 
order to better understand its function as a signaling molecule. To asses this, a knockout 
line was generated using CRISPR-Cas9 and human embryonic kidney (HEK) cells. After 
confirmation of knockout, proliferation studies were conducted on untreated knockout 
and wild-type cells and upon addition of 0-0.5 μg/mL of PMA and 0-5 μg/mL of 
sphingosine-1-phosphate to induce proliferation. Our results indicate that compared 
with wild-type cells, untreated PKCα knockout cells exhibited reduced proliferation and 
had high percentages of cell death when treated with proliferative agents. This supports 
the hypothesis that PKC knockout reduces proliferation in human embryonic kidney 
cells and suggests that PKC has an important role in normal cell function in a tumor-
promoting context.  
 
Keywords: protein kinase C alpha (PKC), proliferation, cancer, knockout, cell signaling 
 1 
Introduction 
 
 Protein kinase C alpha (PKCα), a signaling molecule involved in many cellular 
processes, has an important role in cell growth and proliferation. The exact details of 
this pathway, however, are unknown, and further elucidation on the effects of PKC on 
cell proliferation is needed. In this study, HEK cells were genetically modified using 
CRISPR-Cas9 to generate a cell line lacking PKC. Together with a wild-type HEK cell line, 
these knockout cells were treated with varying levels of proliferative agents, and 
differences in the resulting growth rates were assessed.  Developing a PKC gene 
knockout cell line and assessing proliferation of these cells increases our understanding 
of the PKC signaling pathway, helps to elucidate its involvement in cell growth and 
division, and contributes to hypotheses of the role it may play in the abnormal 
proliferation that is characteristic of cancer cells. In short, our findings contribute to the 
foundation for future applications of PKC involvement in cell proliferation. 
  
 2 
Review of Literature 
PKC function 
 Cancer is the result of uncontrolled cell growth and is the second largest cause of 
death in the United States [5]. This abnormal cell growth is attributed to cancer-causing 
mutations that typically involve malfunction of tumor-suppressor genes and the 
activation of proteins involving cell proliferation. In fact, many cancers are known to 
involve a mutation in TP53, a tumor-suppressor gene [12]. Without the proper function 
of the protein produced by that gene, p53, cell growth and division are largely 
unregulated [12]. This results in abnormal growth, often initiated by cell signaling 
molecules that have a role in normal, non-cancerous cell proliferation. One of these 
signaling molecules, an enzyme called protein kinase C alpha (PKCα), is activated in 
normal cells by diverse signaling pathways. Various stimuli, often involving interaction 
with a membrane, can lead to PKC involvement in differentiation, apoptosis, cellular 
transformation, motility, cell growth, proliferation, and many other cellular functions 
[13]. Importantly, PKC has been linked to proliferation, survival, differentiation and 
motility in tumor growth, but can also act as a tumor suppressor depending on the 
context [4]. In fact, past research has shown that PKC activation leads to the 
progression of many cancers (for example, bladder and breast cancer), while it may act 
as a growth-inhibitory kinase in others (such as colon cancer and non-small cell lung 
cancer) [1], [4], [10]. Its role in cell proliferation as an application of tumor promotion is, 
however, not well understood, but targeting PKC as a potential therapy for many 
cancers has been suggested [4]. In order to understand more about how aberrant PKC 
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signaling may be contributing to the rapid growth and division of cancer cells, a better 
understanding of the functional diversity of its proliferative role in cells is needed.  
Gene knockout and human embryonic kidney cells 
There are two common methods used to understand protein function: 
genetically modifying a cell line to render the gene nonfunctional, and utilizing drug 
inhibition to block protein function. In the inhibition method, proteins are still present, 
so although function is impaired, it is still possible for the drug-inhibited protein to 
interact with binding partners. Drug inhibition often also has off-target effects [16], and 
thus an agent used to inhibit PKC function may also interfere with molecules involved 
in other proliferation pathways. For example, UCN-01 is a PKC inhibitor with anti-
tumor applications, but because it does not work exclusively via the PKC pathway it 
cannot be used to understand the specific role of PKC in proliferation and tumor 
promotion [4]. In contrast, gene knockout prevents the production of the protein 
altogether and eliminates the problems associated with inhibition. Because it exclusively 
targets the gene that codes for a protein, gene knockout yields more specific results. 
Knocking out the gene for PKC in human embryonic kidney (HEK) cells would generate 
a cell line that could serve as a comparison to wild-type HEK cells with a normal 
functioning PKC gene.  
HEK cells are commonly used in cell biology and cancer research for many 
reasons: they are easy to grow and transfect, relatively inexpensive, and tumorigenic 
[15]. These properties make HEK cells a practical and meaningful tool for use in a study 
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involving gene-knockout and cell proliferation. Additionally, PKC does not act as an 
anti-proliferative factor in HEK cells, so this cell line serves as an excellent model for 
better understanding the functional role of PKC in proliferation and tumor promotion 
[13]. A common concern involving gene-knockout involves cell viability. Removing a 
gene can have drastic effects and is often too significant of an alteration for the cells to 
survive. In 2002, researches developed a method of targeting PKC isotypes in HEK-293 
cells and demonstrated that subtype-specific differentiation was possible [6]. 
Specifically, they performed subtype-specific knockdown of PKC on HEK cells using short 
interfering RNA and grew them in normal conditions. Although this is not the same as 
gene knockout with CRISPR-Cas9, the survival of these HEK cells without active PKC 
suggests that CRISPR-Cas9-generated PRKCA knockout HEK cells would be viable for use 
in proliferation studies.  
CRISPR-Cas9 
CRISPR-Cas9 is a relatively new technology that can be used for gene knockout. 
Since the first discovery of a CRISPR locus in 1993, CRISPR-Cas9 has been researched 
extensively [7]. In 2013, researchers used it to genetically modify the genes of mice and 
mark them with a fluorescent reporter. Analysis verified that the CRISPR-Cas9 
mechanism rarely makes errors and the use of this technology in eukaryotic cells is 
effective, efficient, and accurate [17]. Continuing this work, in 2014 CRISPR-Cas9 was 
successfully used for gene knockout in HEK-293 cells [18]. Similarly, this system could be 
employed to create a HEK cell line without PRKCA, the PKC gene. Because of its use 
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and reliability in genetic modification, CRISPR-Cas9 is important for cancer research and 
understanding the role of specific proteins, such as PKC, in cell proliferation. 
Additionally, our use of CRISPR-Cas9 in this study makes this method accessible as a 
research and teaching tool at Olivet. The successful use of the CRISPR-Cas9 mechanism 
will contribute to the development of laboratory protocol so that this tool could be 
widely used by Olivet biology students.   
Cell proliferation and proliferative agents 
 PKC isoforms are classified into several groups. PKC falls into the category of 
classical PKCs (cPKCs). cPKCs are activated at a C1 domain and a C2 domain. The C1 
domain is activated by diacylglycerol (DAG), a secondary messenger that is stimulated 
by membrane receptors, and the C2 domain allows for the binding of other molecules in 
the presence of calcium [13]. A phorbol ester, such as phorbol 12-Myristate 13-Acetate 
(PMA), is a proliferative agent known to utilize the PKC pathway by binding at the C1 
domain [11]. Another proliferative agent, sphingosine-1-phosphate, causes proliferation 
independent of PKC signaling [2]. The mechanism of proliferation via PKC can differ 
depending on the cell type and activity. Activated PKC has been documented to 
upregulate cyclin-D1, cdk4 and p21cip1, all of which can enhance proliferation [13]. 
Commonly, PKC phosphorylates Raf-1, which leads to the activation of ERK-MAPK 
(extracellular signal-regulated kinase-mitogen-activated protein kinase cascade) [13]. 
This enhances proliferation in many cell types, including HEK-293 cells [19]. PKCα 
dependent and independent proliferation in HEK cells can be evaluated through visual 
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observation and the generation of a cell growth curve with doubling times. This can be 
calculated using a Hemocytometer over a period of several days. In order to evaluate 
the effects of proliferative agents on cell proliferation, cells can be treated with various 
concentrations of the proliferative agent, counted, and then used to construct a 
concentration vs. cell proliferation curve.   
PKC has an important role in cell proliferation, but it is functionally diverse and 
largely not understood. Because of its involvement in tumor promotion, understanding 
this protein and its signaling pathway is important and relevant for cancer research and 
treatment. Investigating the effects of PRKCA knockout on proliferation in a cell line 
where PKC is not tumor-suppressive can help fill this gap in research. Specifically, 
attempting to induce abnormal proliferation by mechanisms that are PKC independent 
and dependent in a PRKCA knockout cell line will yield further understanding of its exact 
role in tumor promotion. We hypothesized that proliferation studies of wild-type and 
knockout cells under both normal conditions and when treated with PKC-independent 
and PKC-dependent proliferation agents would demonstrate that knocking out protein 
kinase C-alpha reduces proliferation in HEK-293 cells.  
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Methodology 
Generation of PRKCA knockout cells 
 PRKCA knockout cells were produced following the manufacture protocol 
provided by Santa Cruz Biotechnology [3]. Briefly, HEK-293 cells were seeded at a 
density of 50,000 cells/well and grown in 24-well culture dishes in Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum. Approximately 48 
hours later, cells reached 60-75% confluence, and culture media was replaced with 
media generated for optimal transfection of HEK-293 cells [14]. This media contained 
both the CRISPR-Cas9 KO plasmid and the homology-directed repair (HDR) plasmid with 
a fluorescent tag and also a puromycin-resistant gene insert prepared according to the 
manufacture’s protocol [3]. Briefly, three tubes were incubated then combined and 
added to each well. Tube A contained 240 μl of Optimem medium and 3.2 μg of the 
CRISPR-Cas9 KO plasmid. Tube B contained 240 μl of Optimem medium and 3.2 μg of 
the HDR plasmid. Tube C contained 400 μl of Optimem medium and 16 μl of 
Lipofectamine 2000. These tubes were incubated individually for 5 minutes at room 
temperature, then mixed gently and the combined solution was incubated for 20 
minutes at room temperature. Following incubation, 115 μl of the final solution was 
added to each well (12 total) with rocking. After 24 hours, this media was replaced with 
standard DMEM and cells were grown in normal culture conditions.  
 Approximately 7 days post-transfection, cells were observed with fluorescent 
microscopy to confirm transfection efficiency by fluorescence. Cells were then grown 
and treated with 2.5 μg/mL of puromycin to kill cells lacking the transfected puromycin-
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resistant gene insert. This selected for cells likely to be PRKCA knockout cells. After 
growing cells for an additional 7 days, they were treated with 10 μg/mL of puromycin to 
select for highly-expressing homozygous knockout cells. 
Western blot analysis of PKCα knockout 
Puromycin resistant cells were grown and tested for PKC presence using 
standard Western blot techniques [8]. Wild-type and knockout cells were grown in 
normal conditions in 6-well culture dishes until they reached confluence. Upon reaching 
confluence, cells were washed with PBS and treated with a lysis buffer containing RIPA 
buffer (Sigma R0278) and four protease inhibitors: PMSF (100mM), Luepeptin (10 
mg/mL), Aprotinin (10 mg/mL), and Pepstatin A (1mg/mL). Lysed cells were collected, 
washed and centrifuged, and a BCA assay was performed to determine protein 
concentration in the cell lysate for wild-type and knockout cells. Lysates were diluted to 
a concentration of 1 mg/mL with SDS-PAGE loading buffer. 10% SDS-PAGE gel (Lonza) 
was loaded with 20 μl of cell lysate per lane. Three lanes were loaded for each cell type, 
and two lanes were loaded with protein molecular weight ladders. This procedure was 
run at a constant voltage of 125 V for approximately 90 minutes. Western blot protocol 
was taken from the Xcell II Blot Module User’s Manual. Transfer to the Western blot 
membrane was performed overnight in a cold room at a constant voltage of 12 V. 
Following this, the membrane was removed, treated with blocking buffer, and 
incubated in primary antibody overnight. Primary antibody was prepared at a dilution of 
1:500. Following this, the membrane was washed and treated with the secondary 
antibody for 1 hour. The secondary antibody was prepared at a dilution of 1:12,500. 
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Remaining western blot procedures took place in a photography dark room. The 
membrane was incubated in ECL Western Blotting Substrate (ThermoFischer) then 
exposed to film for times ranging from 10 to 45 seconds. Film was developed in 
developer solution for 2-3 minutes, placed in water for 30 seconds, placed in fixer for 3 
minutes, and then rinsed under running water for 5 minutes.  
Treatment with proliferative agents: sphingosine-1-phosphate and phorbol ester 
PRKCA knockout and wild-type HEK-293 cells were first grown in normal 
conditions to determine viability and disruption of the normal cell cycle. Cells were 
grown in the absence of puromycin to prevent altered proliferation compared to wild-
type cells. Cell counts were recorded for each group in duplicate over a 4 day period. 
Next, knockout and wild-type cells were treated with proliferative agents. The first of 
these proliferative agents, sphingosine-1-phosphate, is known to work via PKC-
independent mechanism in HEK-293 cells [2]. Knockout and wild-type cell cultures were 
treated with concentrations of sphingosine-1-phosphate ranging from 0-5 μg/mL, and 
observations of percent confluence were recorded. The second proliferative agent, 
phorbol ester, is known to activate PKCα by mimicking diacylglycerol, the physiological 
ligand for PKC that binds along with calcium for normal PKC activation [11]. Unlike 
diacylglycerol, phorbol ester does not also require the binding of calcium to induce 
proliferation [11]. Knockout and wild-type cell cultures were treated with 
concentrations of phorbol ester ranging from 0-0.5 μg/mL, and observations of percent 
confluence were recorded.   
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Statistical analysis 
A student’s t-test was used to assess significance of PKCα in cell proliferation, 
with a p-value less than or equal to 0.05 considered statistically significant.  
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Results 
Establishing a working concentration of puromycin 
 In order to select for potential knockout cells using puromycin, it was important 
to establish a minimum level of puromycin that is toxic to wild-type HEK-293 cells. Based 
on previous literature, a treatment was conducted using concentrations of 0, 2, 2.5 and 
3 μg/mL puromycin. Within two days of treatment, concentrations of 2.5 and 3 μg/mL 
resulted in 100% cell death. A puromycin concentration of 2.5 μg/mL was then selected 
to be used to treat transfected cells.  
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Figure 1. Puromycin dose response curve in HEK cells two days after treatment. Cells 
were treated with concentrations of 0, 2, 2.5 and 3 μg/mL of puromycin. A 
concentration of 2.5 μg/mL resulted in 100% cell death.  
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Confirmation of knockout 
 All cells were observed for RFP expression 24 hours after transfection. As 
expected, wild-type cells demonstrated a complete absence of RFP expression, and RFP 
was observed at varying levels in transfected cells. Transfected cells treated with 2.5 
μg/mL of puromycin resulted in some cell death, but surviving cells displayed normal, 
healthy growth. Control cells were treated simultaneously with 2.5 μg/mL puromycin 
and resulted in 100% cell death. The remaining transfected cells were then observed 
under fluorescent microscopy to analyze RFP expression. Figure 2 shows photographs 
depicting RFP expression in transfected cells before treatment with puromycin and one 
week post-treatment.  
  
 
 
 
 
  
 
 
 
Figure 2. RFP expression using fluorescent microscopy in transfected cells before and 
after puromycin selection. Few transfected cells expressed RFP before puromycin 
selection (A), and RFP was observed at much higher levels in transfected cells after 
selection with puromycin (B).  
A B 
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Observations and cell counts for untreated cells 
 To monitor the general health of the knockout cell line, observations were made 
in comparison to wild-type HEK-293 cells. Transfected cells maintained consistent 
appearances with the wild-type cells and grew without much difficultly. They did, 
however, appear to grow at a slower rate than control cells. Cell counts were recorded 
to confirm this observation, where the cell doubling time of wild-type HEK-293 cells was 
determined to be 1.11 ± 0.04 days, while the doubling time of PRKCA KO cells was over 
twice as long at 2.27 ± 0.44 days (Figure 3, p=0.045).  
 
 
 
 
 
 
 
 
Observations of cells treated with sphingosine and PMA  
As quiescent PRKCA knockout cells grew more slowly, we also sought to 
determine if inducing proliferation would result in aberrant growth in PRKCA knockout 
Figure 3. Cell doubling times in PRKCA knockout and wild-type HEK-293 cells. 
Doubling times were calculating from cell counts over a four day period. Wild-type: 
mean = 1.11 days, SE = 0.04. KO: mean = 2.27 days, SE = 0.44.  
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cells.  Treatments with sphingosine (Figure 4A) and PMA (Figure 4B) were completed. As 
demonstrated in Figure 4, these observations resulted in very high levels of growth for 
control cells treated with all concentrations of PMA and sphingosine. All wild-type cells 
reached confluence within 48 hours (data not shown). Contrary to this observation, 
transfected cells treated with PMA and sphingosine did not demonstrate observable 
growth within 48 hours. By 96 hours (four days), treated transfected cells demonstrated 
high levels of death ranging from 75-100% (Figure 4A and 4B).  These results indicate 
that PKCα plays a central role in proliferative induction by both PMA and sphingosine 
signaling pathways.   
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Figure 4. PKCα knockout cells treated with sphingosine (A) and PMA (B) exhibit 
reduced viability over time. A: Cells were treated with concentrations of 0, 0.1, 1 and 
5 μg/mL of sphingosine-1-phosphate. B: Cells were treated with concentrations of 0, 
0.162, 0.3 and 0.5 μg/mL of PMA. Confluence was assessed four days post-treatment 
and was observed in two cell culture wells for each cell type and treatment group.  
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Discussion 
 Determination of the role of PKC in cell proliferation was desired, so the PRKCA 
gene knockout was attempted, growth in normal conditions assessed, and the effects of 
treating knockout cells with PKC-dependent and independent proliferation agents 
observed. 
Knockout or homozygosity? 
 Within 2 days of transfection, RFP expression was observed in transfected cells in 
varying amounts. Some of this can be attributed to the fact that transfection was not 
successful in all treated cells. In cells displaying at least some level of RFP, however, one 
possible explanation for differing levels of expression involves transient expression of 
the HDR plasmid. Transient expression occurs when the plasmid has not been 
incorporated into the genome but is actively being transcribed. To account for this 
possibility, transfected cells were grown for an additional two weeks and underwent an 
additional puromycin treatment. Because transient expression of the HDR plasmid from 
Santa Cruz Biotechnology lasts a maximum of seven days, any expression of RFP over 
two weeks post-transfection should be attributed exclusively to genomic expression of 
the plasmid [3]. The vast majority – approximately 90-95% – of remaining cells 
demonstrated RFP after this additional treatment, which very strongly suggested 
transfection success.  
 Western blot analysis detected PKC expression in both cell lines (data not 
shown). Bands were observed around 80 kDa, the molecular mass of PKC and other 
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isoforms of PKC, in lanes containing wild-type cell lysate as well as lanes containing 
knockout cell lysate. There were no noticeable differences in size or expression between 
the bands in any exposure times. Though this appeared to contradict other indicators of 
knockout success, there are many possible explanations for this observed result. The 
quantity of secondary antibody appropriate for use in this procedure was estimated 
based on previous literature; however, it is highly likely that the amount used was too 
high and resulted in non-specific binding. Because the secondary antibody contains the 
horseradish enzyme that indicates expression during x-ray exposure, non-specific 
binding of this antibody to other forms of PKC would yield similar band expression on 
the final x-ray film and result in a false positive. Future studies could replicate this 
procedure with varying levels of secondary antibody to yield more meaningful results.  
 An additional explanation for varying levels of expression in RFP positive cells 
and the Western blot result involves the genomic location of RFP. Expression of PKC is 
biallelic. Because of this, transfected cells may have been a combination of hemizygous 
and homozygous PRKCA knockout cells. In an attempt to select for highly-expressing 
homozygous knockout cells, we treated transfected cells with 10 g/mL of puromycin 
(four times the concentration that is toxic to wild-type cells) before conducting 
proliferation studies. Cells that survived this treatment were determined to be probable 
knockout cells and were used for all remaining procedures, however it is still possible 
that some of these surviving cells were hemizygous knockout, and this could explain the 
observed expression of PKC in the Western blot analysis.  
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Role of PKCα in homeostatic proliferation 
 Cell growth calculations yielded doubling times of 1.11 ± 0.04 days and 2.27 ± 
0.44 days for untreated wild-type cells and knockout cells, respectively. HEK cells are 
typically expected to have a doubling time of 24 hours, so the calculation of 
approximately a one day doubling time for wild-type cells is consistent with previous 
literature. A statistical analysis comparing the mean doubling times resulted in a p-value 
of 0.045. This suggests that the doubling time of PRKCA knockout cells is significantly 
slower than the doubling time of wild-type cells. Upon further analysis of the data, there 
are two main factors that contributed to the p-value: the small sample size and the high 
level of variance in knockout cells. Though all individual doubling times for knockout 
cells were slower than wild-type cells, they were less consistent. They appeared to take 
an especially long time to grow immediately after attachment. This observation is 
important in our understanding of how PRKCA knockout influences proliferation in HEK 
cells and how varying growth among knockout cells effects the significance of the data. 
Overall, observations and cell counts consistently demonstrated reduced proliferation in 
knockout cells, and a statistical analysis of the data yielded a significant result. In further 
studies, this data should be replicated with a larger sample, but our preliminary data 
demonstrating slowed growth supports the hypothesis that PRKCA gene knockout 
reduces proliferation in HEK cells.  
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Role of PKCα during induction of proliferation 
  Treatments of knockout cells in high concentrations of sphingosine and PMA 
resulted in abnormal levels of cell death. This result was observed in two cell culture 
wells for each group alongside treatment of the same concentrations on wild-type cells 
that experienced rapid growth and reached confluence. To assess the significance of this 
data, it should be replicated with a larger sample size and a wider range of 
concentrations for each proliferation agent. However, we are still able to discuss several 
possible explanations for this observation within our study. Cells that have experienced 
gene knockout are often less stable; gene knockout is an intensive process, and a 
protein such as PKC is important in many cell processes [4]. Inducing proliferation in 
these cells may be received as a stressful signal that the weakened cell cannot endure. 
Additionally, PKC often acts as an anti-apoptotic factor, restricting the cell’s tendency 
to default toward death [13]. Cells without PKC are, then, more likely to begin to 
progress toward apoptosis after receiving an external cellular signal. Because HEK cells 
are tumorigenic and PRKCA knockout cells became apoptotic when stimulated with high 
concentrations of proliferation agents, these data suggest that PKC is important for 
normal cell function in a tumor-promoting context. Moreover, since untreated PRKCA 
knockout cells grew significantly slower than wild-type cells, together, these data 
further highlight the importance of PKCα as a key regulator of cellular proliferation.   
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